Showcasing Claudin18.2 T Cell Engager for GC & PDAC Malignancies
Time: 10:30 am
day: Conference Day 2
Details:
- Reviewing CLDN18.2 expression as a target for GC and PDAC tumours
- Strategies for increasing the therapeutic index of T cell engagers and application to CLDN18.2
- Preclinical data on AZD5863 – a clinical stage CLDN18.2 T cell engager
